When Is It Time to Escalate? Navigating C3G Treatment Decisions

Video content above is prompted by the following:

C3G Treatment: Decision-Making for Therapy Escalation

Key Points for Physicians

Baseline Approach to C3G Management

• Most C3G patients are expected to progress without intervention
• Clinicians should approach C3G with the presumption that immunomodulatory therapy will be needed
• Exceptions (patients who may remain on conservative therapy alone) are relatively rare

Indicators for Escalating Beyond Conservative Management

• Clinical Parameters:
  • Proteinuria >500 mg/day despite conservative therapy
  • Persistent hematuria (≥3+ on dipstick)
  • Declining kidney function
• Histopathological Factors:
  • Higher activity scores on biopsy (>2 on C3G activity index)
  • Significant chronicity at diagnosis (suggesting longstanding disease)
  • Some centers use formal C3G activity and chronicity indices similar to lupus nephritis

Therapeutic Decision-Making Challenges

• Diagnostic Limitations:
  • Restricted availability of genetic testing for complement variants
  • Limited commercial testing for autoantibodies (nephritic factors)
  • Many specialized complement tests only available in research settings
  • Variants of uncertain significance complicate interpretation
• Patient-Specific Factors:
  • Age-related considerations (monoclonal gammopathies in patients ≥40-50 years)
  • Need for clone-directed therapy in monoclonal gammopathy-associated C3G

Future Directions in C3G Management

• Precision Medicine Goals:
  • Match specific complement pathway defects with targeted therapies
  • Utilize whole-genome sequencing to identify relevant genetic variants
  • Develop broader autoantibody testing capabilities
  • Create patient-specific treatment algorithms
• Paradigm Shift in Outcomes:
  • Expectation that targeted therapies will significantly alter progression curves
  • Potential to prevent end-stage kidney disease in young patients
  • Similar therapeutic advances occurring in other glomerular diseases (e.g., IgA nephropathy)

Clinical Implementation Priorities

• Earlier identification and referral of patients with C3G
• Increased awareness that abnormal urinalysis may represent glomerular disease
• Improved access to specialized testing and treatments
• Development of standardized protocols for therapy initiation and monitoring

This new era of targeted complement therapies represents a transformative opportunity to change the natural history of C3G, requiring both diagnostic refinement and strategic implementation of novel treatments.